Short Term Outcomes in Hospitalized Patients With Liver Cirrhosis
Study Details
Study Description
Brief Summary
This study will be conducted to assess the baseline characteristics and evaluate the 90-day mortality of patients admitted with liver cirrhosis. Also, the study will be done to identify the risk factors of 90-day mortality.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
Liver cirrhosis is the end spectrum of all chronic liver diseases characterized by advanced fibrosis, scarring, and formation of regenerative nodules leading to hepatic architectural distortion.
Liver cirrhosis is a major cause of health burden worldwide. According to the Global Burden of Disease study, liver cirrhosis caused 1.2% of global disability-adjusted life years and 2% of all deaths worldwide in 2010, the 14th leading cause of mortality.
The progress rate of compensated cirrhosis to decompensated cirrhosis is approximately 58% and once it progresses to decompensated cirrhosis, its mortality rate within 5 years becomes 85% without liver transplantation. Since the progression of cirrhosis is accelerated each time a complication recurs, the management and treatment of the complication are critical in enhancing the quality of life and the life expectancy of patients .
Post-discharge outcomes are an integral component of healthcare, as they may aid in determining the success and longevity of treatment and how clinicians approach future cases .
This study will focus on the short-term outcomes of patients hospitalized with liver cirrhosis to provide insight into methods for future healthcare interventions.
Study Design
Outcome Measures
Primary Outcome Measures
- evaluate the 90-day mortality of patients admitted with liver cirrhosis [90 days]
Mortality
Secondary Outcome Measures
- identify the risk factors of 90-day mortalit [90 days]
Risk factors for mortality
Eligibility Criteria
Criteria
Inclusion Criteria:
- diagnosis of liver cirrhosis, adult (age ≥ 18 years old) and patients willing to give consent during the selected period.
Exclusion Criteria:
- Patients with ages < 18 years or patients that will be lost on follow-up will be excluded from the study.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Assiut University
Investigators
- Study Director: Ahlam M Farghaly, AhlamGastro2000@yahoo.com
Study Documents (Full-Text)
None provided.More Information
Publications
- Liver cirrhosis mortality